Base de dados : MEDLINE
Pesquisa : E01.370.872 [Categoria DeCS]
Referências encontradas : 2351 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 236 ir para página                         

  1 / 2351 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452210
[Au] Autor:Talley NJ
[Ad] Endereço:Faculty of Health and Medicine, University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
[Ti] Título:Functional Dyspepsia: Advances in Diagnosis and Therapy.
[So] Source:Gut Liver;11(3):349-357, 2017 May 15.
[Is] ISSN:2005-1212
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:Functional dyspepsia (FD) is a common but under-recognized syndrome comprising bothersome recurrent postprandial fullness, early satiety, or epigastric pain/burning. Epidemiologically, there are two clinically distinct FD syndromes (although these often overlap clinically): postprandial distress syndrome (PDS; comprising early satiety or meal-related fullness) and epigastric pain syndrome. Symptoms of gastroesophageal reflux disease overlap with FD more than expected by chance; a subset has pathological acid reflux. The pretest probability of FD in a patient who presents with classical FD symptoms and no alarm features is high, approximately 0.7. Coexistent heartburn should not lead to the exclusion of FD as a diagnosis. One of the most exciting observations in FD has been the consistent finding of increased duodenal eosinophilia, notably in PDS. Small bowel homing T cells, signaling intestinal inflammation, and increased cytokines have been detected in the circulation, and elevated tumor necrosis factor-α levels have been significantly correlated with increased anxiety. Postinfectious gastroenteritis is a risk factor for FD. Therapeutic options remain limited and provide only symptomatic benefit in most cases. Only one therapy is known to change the natural history of FD- eradication. Treatment of duodenal eosinophilia is under investigation.
[Mh] Termos MeSH primário: Dispepsia/diagnóstico
Dispepsia/terapia
Período Pós-Prandial
Avaliação de Sintomas
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Duodenopatias/complicações
Duodenopatias/diagnóstico
Dispepsia/etiologia
Eosinofilia/complicações
Eosinofilia/diagnóstico
Refluxo Gastroesofágico/complicações
Refluxo Gastroesofágico/diagnóstico
Azia/complicações
Azia/diagnóstico
Infecções por Helicobacter/complicações
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.5009/gnl16055


  2 / 2351 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29378685
[Au] Autor:Khin MO; Bromham N; Harrison M; Eadon H; Guideline Committee
[Ad] Endereço:National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, London NW1 4RG, UK.
[Ti] Título:Assessment and management of oesophago-gastric cancer: summary of NICE guidance.
[So] Source:BMJ;360:k213, 2018 01 29.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias Esofágicas/diagnóstico
Neoplasias Esofágicas/terapia
Guias de Prática Clínica como Assunto
Neoplasias Gástricas/diagnóstico
Neoplasias Gástricas/terapia
[Mh] Termos MeSH secundário: Gerenciamento Clínico
Seres Humanos
Avaliação de Sintomas/normas
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180131
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k213


  3 / 2351 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776835
[Au] Autor:Mustian KM; Cole CL; Lin PJ; Asare M; Fung C; Janelsins MC; Kamen CS; Peppone LJ; Magnuson A
[Ti] Título:Exercise Recommendations for the Management of Symptoms Clusters Resulting From Cancer and Cancer Treatments.
[So] Source:Semin Oncol Nurs;32(4):383-393, 2016 11.
[Is] ISSN:1878-3449
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To review existing exercise guidelines for cancer patients and survivors for the management of symptom clusters. DATA SOURCES: Review of PubMed literature and published exercise guidelines. CONCLUSION: Cancer and its treatments are responsible for a copious number of incapacitating symptoms that markedly impair quality of life. The exercise oncology literature provides consistent support for the safety and efficacy of exercise interventions in managing cancer- and treatment-related symptoms, as well as improving quality of life in cancer patients and survivors. IMPLICATIONS FOR NURSING PRACTICE: Effective management of symptoms enhances recovery, resumption of normal life activities and quality of life for patients and survivors. Exercise is a safe, appropriate, and effective therapeutic option before, during, and after the completion of treatment for alleviating symptoms and symptom clusters.
[Mh] Termos MeSH primário: Exercício
Neoplasias/enfermagem
Qualidade de Vida
[Mh] Termos MeSH secundário: Seres Humanos
Sobreviventes
Avaliação de Sintomas
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  4 / 2351 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464924
[Au] Autor:Clark DA; Khan U; Kiberd BA; Turner CC; Dixon A; Landry D; Moffatt HC; Moorhouse PA; Tennankore KK
[Ad] Endereço:Division of Nephrology, Dalhousie University, 5070 Dickson Building, 5820 University Avenue, Halifax, B3H 2Y9, NS, Canada.
[Ti] Título:Frailty in end-stage renal disease: comparing patient, caregiver, and clinician perspectives.
[So] Source:BMC Nephrol;18(1):148, 2017 May 02.
[Is] ISSN:1471-2369
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Frailty is associated with poor outcomes for patients on dialysis and is traditionally measured using tools that assess physical impairment. Alternate measurement tools highlight cognitive and functional domains, requiring clinician, patient, and/or caregiver input. In this study, we compared frailty measures for incident dialysis patients that incorporate patient, clinician, and caregiver perspectives with an aim to contrast the measured prevalence of frailty using tools derived from different conceptual frameworks. METHODS: A prospective cohort study of incident dialysis patients was conducted between February 2014 and June 2015. Frailty was assessed at dialysis onset using: 1) modified definition of Fried Phenotype (Dialysis Morbidity Mortality Study definition, DMMS); 2) Clinical Frailty Scale (CFS); 3) Frailty Assessment Care Planning Tool (provides CFS grading, FACT-CFS); and 4) Frailty Index (FI). Measures were compared via correlation and sensitivity/specificity analyses. RESULTS: A total of 98 patients participated (mean age of 61 ± 14 years). Participants were primarily Caucasian (91%), male (58%), and the majority started on hemodialysis (83%). The median score for both the CFS and FACT-CFS was 4 (interquartile range of 3-5). The mean FI score was 0.31 (standard deviation ± 0.16). The DMMS identified 78% of patients as frail. The FACT-CFS demonstrated highest correlation (r = 0.71) with the FI, while the DMMS was most sensitive (97%, 100%) and a CFS ≥ 5 most specific (100%, 77%) at corresponding FI cutoff values (>0.21, >0.45). CONCLUSIONS: Frailty assessments of incident dialysis patients that include clinician, caregiver and patient perspectives have moderate to strong correlation with the FI. At specified FI cutoff values, the FACT-CFS and DMMS are highly sensitive measures of frailty. The CFS and FACT-CFS may represent viable alternative screening tools in dialysis patients.
[Mh] Termos MeSH primário: Autoavaliação Diagnóstica
Avaliação Geriátrica/métodos
Falência Renal Crônica/diagnóstico
Falência Renal Crônica/terapia
Programas de Rastreamento/métodos
Diálise Renal/estatística & dados numéricos
Índice de Gravidade de Doença
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Atitude do Pessoal de Saúde
Cuidadores/estatística & dados numéricos
Feminino
Fragilidade
Avaliação Geriátrica/estatística & dados numéricos
Seres Humanos
Falência Renal Crônica/epidemiologia
Masculino
Meia-Idade
Nova Escócia/epidemiologia
Satisfação do Paciente/estatística & dados numéricos
Prevalência
Reprodutibilidade dos Testes
Fatores de Risco
Sensibilidade e Especificidade
Avaliação de Sintomas/métodos
Avaliação de Sintomas/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12882-017-0558-x


  5 / 2351 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461530
[Au] Autor:Kaskas N; Merola JF; Qureshi AA; Paek SY
[Ad] Endereço:From the Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
[Ti] Título:Polyphenotypic Psoriasis: A Report from the GRAPPA 2016 Annual Meeting.
[So] Source:J Rheumatol;44(5):695-696, 2017 May.
[Is] ISSN:0315-162X
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:Recent groundbreaking therapies for psoriasis target specific pathways that drive this systemic inflammatory disease. However, patients with nonplaque psoriasis phenotypes often do not qualify for these therapies and are currently undertreated because of the criteria used during the development of novel agents. We propose use of the phrase "polyphenotypic psoriasis" to describe both plaque and nonplaque subtypes, as well as single and multiple phenotype involvement in individual patients. The goal of using the phrase "polyphenotypic psoriasis" is to remind clinicians about the heterogeneous manifestations of psoriasis in addition to chronic plaque psoriasis.
[Mh] Termos MeSH primário: Psoríase/diagnóstico
Pele/patologia
[Mh] Termos MeSH secundário: Fármacos Dermatológicos/uso terapêutico
Seres Humanos
Psoríase/tratamento farmacológico
Psoríase/patologia
Índice de Gravidade de Doença
Avaliação de Sintomas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermatologic Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.3899/jrheum.170149


  6 / 2351 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463161
[Au] Autor:Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
[Ad] Endereço:Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Electronic address: ebasch@med.unc.edu.
[Ti] Título:Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):409-418, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter clinical trial using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). METHODS AND MATERIALS: Patients enrolled in NRG Oncology's RTOG 1012 (Prophylactic Manuka Honey for Reduction of Chemoradiation Induced Esophagitis-Related Pain during Treatment of Lung Cancer) were asked to self-report 53 PRO-CTCAE items representing 30 symptomatic AEs at 6 time points (baseline; weekly ×4 during treatment; 12 weeks after treatment). Reporting was conducted via wireless tablet computers in clinic waiting areas. Compliance was defined as the proportion of visits when an expected PRO-CTCAE assessment was completed. RESULTS: Among 226 study sites participating in RTOG 1012, 100% completed 35-minute PRO-CTCAE training for clinical research associates (CRAs); 80 sites enrolled patients, of which 34 (43%) required tablet computers to be provided. All 152 patients in RTOG 1012 agreed to self-report using the PRO-CTCAE (median age 66 years; 47% female; 84% white). Median time for CRAs to learn the system was 60 minutes (range, 30-240 minutes), and median time for CRAs to teach a patient to self-report was 10 minutes (range, 2-60 minutes). Compliance was high, particularly during active treatment, when patients self-reported at 86% of expected time points, although compliance was lower after treatment (72%). Common reasons for noncompliance were institutional errors, such as forgetting to provide computers to participants; patients missing clinic visits; Internet connectivity; and patients feeling "too sick." CONCLUSIONS: Most patients enrolled in a multicenter chemoradiotherapy trial were willing and able to self-report symptomatic AEs at visits using tablet computers. Minimal effort was required by local site staff to support this system. The observed causes of missing data may be obviated by allowing patients to self-report electronically between visits, and by using central compliance monitoring. These approaches are being incorporated into ongoing studies.
[Mh] Termos MeSH primário: Quimiorradioterapia/efeitos adversos
Esofagite/complicações
Neoplasias Pulmonares/terapia
Microcomputadores/estatística & dados numéricos
Dor/prevenção & controle
Cooperação do Paciente/estatística & dados numéricos
Medidas de Resultados Relatados pelo Paciente
Autorrelato/utilização
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Apiterapia/métodos
Transtornos de Deglutição/etiologia
Transtornos de Deglutição/terapia
Estudos de Viabilidade
Feminino
Mel
Seres Humanos
Internet
Masculino
Meia-Idade
National Cancer Institute (U.S.)
Avaliação de Sintomas/estatística & dados numéricos
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  7 / 2351 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471115
[Au] Autor:Mao XC; Yu WQ; Shang JB; Wang KJ
[Ad] Endereço:Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou 310011, China.
[Ti] Título:Clinical characteristics and treatment of thyroid cancer in children and adolescents: a retrospective analysis of 83 patients.
[So] Source:J Zhejiang Univ Sci B;18(5):430-436, 2017 May.
[Is] ISSN:1862-1783
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To study the clinical characteristics, treatment, and prognosis of thyroid cancer in children and adolescents. METHODS: We performed a retrospective analysis of clinical data from 83 cases of thyroid cancer in children and adolescents from January 1990 to December 2010. We compared extra-thyroid extension, lymph node metastasis, distant metastasis, and prognosis between pediatric patients ≤12 years of age (27 cases) and those >12 years of age (56 cases). All the patients agreed to undergo thyroidectomy and endocrine therapy, and the consent was obtained from parents or guardians. RESULTS: Histopathology included papillary carcinoma in 67 cases, papillary carcinoma with partial follicular growth pattern in 1 case, papillary carcinoma with squamous metaplasia in 4 cases, follicular carcinoma in 7 cases, medullary carcinoma in 3 cases, and poorly differentiated carcinoma in 1 case. The total lymph node metastasis rate was 78.31%. Patients ≤12 years of age showed a higher rate of lymph node metastasis than the older group (92.59% vs. 71.43%, P=0.028). The incidence rate in females in the older group was higher than that in the younger group (80.36% vs. 59.26%, P=0.041). There were no significant differences in extra-thyroid extension, distant metastasis, survival rate, or recurrent disease between the two groups. CONCLUSIONS: The lymph node metastasis of thyroid cancer is higher in patients ≤12 years of age than in those >12 years of age; the incidence rate is higher in females than in males. Childhood thyroid cancer has a good prognosis, surgery being the most effective treatment. Choosing a reasonable surgery method and comprehensive postoperative treatment can achieve a cure and satisfactory survival rate.
[Mh] Termos MeSH primário: Terapia de Reposição Hormonal/mortalidade
Avaliação de Sintomas/métodos
Neoplasias da Glândula Tireoide/diagnóstico
Neoplasias da Glândula Tireoide/terapia
Tireoidectomia/mortalidade
[Mh] Termos MeSH secundário: Adolescente
Distribuição por Idade
Criança
Pré-Escolar
China/epidemiologia
Diagnóstico Diferencial
Feminino
Terapia de Reposição Hormonal/utilização
Seres Humanos
Lactente
Recém-Nascido
Metástase Linfática
Masculino
Prevalência
Fatores de Risco
Distribuição por Sexo
Taxa de Sobrevida
Neoplasias da Glândula Tireoide/mortalidade
Tireoidectomia/utilização
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1631/jzus.B1600308


  8 / 2351 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29235093
[Au] Autor:Di Minno MND; Napolitano M; Dolce A; Mariani G; STER Study Group
[Ad] Endereço:Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
[Ti] Título:Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry.
[So] Source:Br J Haematol;180(4):563-570, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Perioperative bleeding is a major concern in patients with factor VII (FVII) deficiency. Evaluating data of 95 FVII-deficient patients undergoing 110 surgical procedures (61 major, 49 minor), we assessed the impact of type of surgery, bleeding phenotype and FVII coagulant activity (FVII:C) levels on perioperative replacement therapy (RT). Compared to those with higher FVII:C levels, patients with <3% FVII:C received a higher number of RT doses (8 vs. 2, P = 0·003) for a longer RT duration (3 days vs. 1 day, P = 0·001), with no difference in RT dose. Similarly, patients with a history of major bleeds received a higher number of RT doses (8·5 vs. 2-3, P = 0·013) for a longer RT duration (2 days vs. 1 day, P = 0·005) as compared to those with a history of minor bleeds or to asymptomatic patients. No difference in RT was found among major and minor surgical procedures. Overall, multivariate analysis showed that history of major bleeding was the only independent predictor of number of RT doses (ß = 0·352, P = 0·001) and RT duration (ß = 0·405, P = 0·018). Overall, a ≈20 µg/kg perioperative RT was efficacious in 95·5% of cases. The infusion should be repeated ≈8 times in high-risk subsets (i.e. patients with a history of major bleeding).
[Mh] Termos MeSH primário: Deficiência do Fator VII/diagnóstico
Deficiência do Fator VII/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Tomada de Decisão Clínica
Terapia Combinada
Gerenciamento Clínico
Fator VII/administração & dosagem
Deficiência do Fator VII/epidemiologia
Feminino
Hemorragia/etiologia
Hemorragia/cirurgia
Seres Humanos
Masculino
Meia-Idade
Sistema de Registros
Procedimentos Cirúrgicos Operatórios/métodos
Avaliação de Sintomas
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
9001-25-6 (Factor VII)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15055


  9 / 2351 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776834
[Au] Autor:Rodgers C; Hooke MC; Ward J; Linder LA
[Ti] Título:Symptom Clusters in Children and Adolescents with Cancer.
[So] Source:Semin Oncol Nurs;32(4):394-404, 2016 11.
[Is] ISSN:1878-3449
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To report evidence regarding assessment methods and management strategies for symptom clusters among children and adolescents with cancer. DATA SOURCES: Published research and clinical guidelines. CONCLUSION: Although a number of studies have identified multiple co-occurring symptoms in children and adolescents with cancer, only a few have included analyses aimed at identifying symptom clusters. Evidence is limited for symptom cluster management strategies. IMPLICATIONS FOR NURSING PRACTICE: Researchers and clinicians need to employ mechanisms that support children and adolescents to: 1) fully express multiple, co-occurring symptoms; 2) identify symptom clusters within specific developmental and diagnostic groups; and 3) develop and evaluate interventions targeting symptom clusters.
[Mh] Termos MeSH primário: Neoplasias/diagnóstico
Avaliação de Sintomas
[Mh] Termos MeSH secundário: Adolescente
Criança
Seres Humanos
Neoplasias/complicações
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  10 / 2351 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776832
[Au] Autor:Lynch Kelly D; Dickinson K; Hsiao CP; Lukkahatai N; Gonzalez-Marrero V; McCabe M; Saligan LN
[Ti] Título:Biological Basis for the Clustering of Symptoms.
[So] Source:Semin Oncol Nurs;32(4):351-360, 2016 11.
[Is] ISSN:1878-3449
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Identification of biologic pathways of symptom clusters is necessary to develop precision therapies for distressing symptoms. This review examined extant literature evaluating relationships between biomarkers and symptom clusters in cancer survivors. DATA SOURCES: PubMed, CINAHL, Web of Science and Cochrane Library were searched using terms "biological markers" or "biomarkers" and "symptom cluster" or "symptom complex" or "multiple symptoms." CONCLUSION: Biomarkers related to inflammation (eg, cytokines) were the most studied and showed the most significant relationships with clusters of symptoms. This review suggests that clustering of symptoms related to cancer or cancer therapy is linked to immune/inflammatory pathways. IMPLICATIONS FOR NURSING PRACTICE: Understanding the etiology of symptom clusters may guide future nursing interventions for symptom management.
[Mh] Termos MeSH primário: Neoplasias/diagnóstico
Avaliação de Sintomas
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, N.I.H., INTRAMURAL
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE



página 1 de 236 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde